Literature DB >> 3319603

Nonsecreting pituitary tumors.

A Klibanski1.   

Abstract

Nonfunctioning pituitary adenomas represent approximately 25 per cent of all clinically apparent pituitary tumors. The tumors are usually macroadenomas and present with symptoms caused by mass effect or hypopituitarism. In addition to structural studies and assessment of pituitary hormone function, all patients with clinically nonfunctioning tumors should have an alpha-subunit determination. High normal or elevated gonadotropins in this setting are suspicious for an underlying gonadotroph adenoma. Alpha subunit, LH-beta, and FSH-beta can be measured in the serum of some patients with nonfunctioning adenomas. Other groups of patients may have tumors in which defects in hormone biosynthesis or processing prevent detectable hormone hypersecretion, or no hormones are produced. The majority of nonfunctioning adenomas have evidence of gonadotropin or glycoprotein hormone subunit production when studied in vitro. An additional tumor group has evidence of ACTH production without biochemical hypercortisolism. Transsphenoidal decompression is the treatment of choice for patients with nonfunctioning adenomas. Pituitary function may improve following surgery in a subset of patients. Postoperative conventional radiotherapy is recommended when there is evidence of residual tumor and/or extensive extrasellar extension preoperatively.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3319603

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  17 in total

1.  Pituitary Adenomas.

Authors:  Grant T. Liu
Journal:  Curr Treat Options Neurol       Date:  2002-07       Impact factor: 3.598

2.  Metamorphosis of a non-functioning pituitary adenoma to Cushing's disease.

Authors:  E U Tan; M S Ho; C R Rajasoorya
Journal:  Pituitary       Date:  2000-10       Impact factor: 4.107

3.  Immunohistochemical evaluation of the post-translational processing of chromogranin A in human pituitary adenomas.

Authors:  A P Heaney; W J Curry; K M Pogue; V L Armstrong; M Mirakhur; B Sheridan; C F Johnston; K D Buchanan; A B Atkinson
Journal:  Pituitary       Date:  2000-10       Impact factor: 4.107

4.  Proliferation markers in different types of clinically non-secreting pituitary adenomas.

Authors:  S Schreiber; W Saeger; D K Lüdecke
Journal:  Pituitary       Date:  1999-05       Impact factor: 4.107

5.  Estrogen receptor beta mRNA expression in normal and adenomatous pituitaries.

Authors:  N J Gittoes; C J McCabe; M C Sheppard; J A Franklyn
Journal:  Pituitary       Date:  1999       Impact factor: 4.107

Review 6.  Endocrine inactive and gonadotroph adenomas: diagnosis and management.

Authors:  M Losa; P Mortini; R Barzaghi; A Franzin; M Giovanelli
Journal:  J Neurooncol       Date:  2001-09       Impact factor: 4.130

7.  Pituitary oncocytomas: clinical features, characteristics in cell culture, and treatment recommendations.

Authors:  D L Silbergeld; M R Mayberg; M S Berger; F Ali-Osman; W A Kelly; C M Shaw
Journal:  J Neurooncol       Date:  1993-04       Impact factor: 4.130

8.  Effect of surgery and radiotherapy on visual and endocrine function in nonfunctioning pituitary adenomas.

Authors:  A Colao; G Cerbone; P Cappabianca; D Ferone; A Alfieri; F Di Salle; A Faggiano; B Merola; E de Divitiis; G Lombardi
Journal:  J Endocrinol Invest       Date:  1998-05       Impact factor: 4.256

9.  Oncocytomas and null cell adenomas of the human pituitary: morphometric and in vitro functional comparison.

Authors:  S Yamada; S L Asa; K Kovacs
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1988

10.  Clinically nonfunctioning pituitary tumors are monoclonal in origin.

Authors:  J M Alexander; B M Biller; H Bikkal; N T Zervas; A Arnold; A Klibanski
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.